Taktile Secures $110M in Goldman Sachs-led Series C to Power AI Transformation in Financial Institutions
24.6.2026 15:30:00 CEST | Business Wire | Press Release
Taktile, the leader in AI transformation for financial institutions, today announced its $110 million Series C fundraise. Growth Equity at Goldman Sachs Alternatives led the round, with participation from Balderton Capital, Index Ventures, Tiger Global, Y Combinator, and Dig Ventures.
Taktile Fast Facts
- Taktile enables banks and insurers to transform into AI-native organizations that are increasingly powered by autonomous agents.
- Demand for Taktile accelerated in 2025, as AI models became capable of automating high-stakes decisions that previously required hours of manual work—from underwriting business loans and assessing claims to catching financial crime.
- Customers automate and optimize decisions with Taktile by combining its financial services expertise and product built for sector-specific AI use cases. One of the world’s largest insurers is running multiple use cases on Taktile, with projected cost efficiencies of over $90M in claims processing alone.
- Taktile’s team has a proven track record of bringing AI agents into production within complex enterprises. Trusted by customers including Mercury, Monzo, Faire, and Pleo, the company has powered outcomes such as 95% automation in B2B underwriting and 75% fewer anti-money laundering (AML) false positives.
Taktile’s most recent breakthrough came in December 2025, when the company's applied AI research institute, Taktile Labs, found that frontier models had crossed a critical threshold. AI could now handle the kind of high-stakes decisions that financial institutions had long reserved for human experts: Moody's reports that financial institutions are spending an average of $72.9 million annually on KYC and AML operations alone.
For the first time, AI is capable of reliably automating much of this repetitive, time-consuming work. But banks and insurers still need a way to operationalize autonomous agents reliably and at scale, so they can empower their workforce with this vital new tool. While generalist AI labs provide raw building blocks to engineers, Taktile gives institutions a way to operate AI-driven decisions within a system that business owners—from heads of credit to fraud officers—can understand and control.
"General purpose AI tooling is fine for simple automations, but it isn’t sufficient for operating mission-critical financial decisions where errors can cost millions," said Taktile CEO and Co-Founder Maik Taro Wehmeyer. "Today, thousands of employees process these decisions manually. Leaders want to redeploy that capacity to higher-value work, while ensuring every outcome—whether human or AI-driven—remains the best for the business and customers. This is what Taktile enables.”
"Taktile stands out for combining deep technical sophistication with a clear understanding of how regulated financial institutions actually operate. They work with a broad spectrum of financial institutions to build, test and automate complex workflows that meet their specific needs," said Christian Resch, Partner in Growth Equity at Goldman Sachs Alternatives.
"Banks and insurers consistently tell us that Taktile has helped them transform how their teams make decisions with AI—unlocking faster product launches, sharper risk outcomes, and meaningful operational efficiency," added Jade Mandel, Managing Director in Growth Equity at Goldman Sachs Alternatives. "Taktile has built something rare: a team and a product that enables financial institutions to unlock real value from AI where it's most complex—inside high-stakes, regulated decisions. We're excited to partner with Maik, Max, and the Taktile team."
Taktile will use the capital to further enhance its AI solutions for complex banking and insurance use cases, and expand its global footprint across the US, EMEA, and LATAM.
About Taktile
Taktile enables financial institutions to transform into AI-native organizations that are increasingly powered by autonomous agents. With our modular Agentic Decision Platform, customers combine AI agents, rules, relevant context, and human oversight to safely automate and optimize their decisions—approving more customers, reimbursing claims instantly, stopping fraud before it spreads, and financing every business worth funding. Founded in 2020, Taktile powers millions of decisions daily for institutions including Mercury, Monzo, Faire, and Pleo. With offices in New York, Berlin, London, São Paulo, and Iași, the company has raised $184M from Growth Equity at Goldman Sachs Alternatives, Index Ventures, Tiger Global, Balderton Capital, and Y Combinator. Learn more at taktile.com.
About Growth Equity at Goldman Sachs Alternatives
Goldman Sachs (NYSE: GS) is one of the leading investors in alternatives globally, with over $625 billion in assets and more than 30 years of experience. The business invests in the full spectrum of alternatives including private equity, growth equity, venture capital, private credit, real estate, infrastructure, sustainability, and hedge funds. Clients access these solutions through direct strategies, customized partnerships, and open-architecture programs.
The alternative investments platform is part of Goldman Sachs Asset Management, which delivers investment and advisory services across public and private markets for the world’s leading institutions, financial advisors and individuals. Goldman Sachs has approximately $3.7 trillion in assets under supervision globally as of March 31, 2026.
Since 2003, Goldman Sachs Growth Equity has invested over $13 billion in companies led by visionary founders and CEOs. The team focuses on investments in growth stage and technology-driven companies spanning multiple industries, including enterprise technology, financial technology, consumer and healthcare. Follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260624880263/en/
Contacts
Media Contact
Nadia Bovy
nadia.bovy@taktile.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press Release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press Release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press Release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press Release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press Release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom